Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Jun 3, 2011


Thermo Fisher Scientific announced that it will be launching three new mass spec instruments at the American Society for Mass Spectrometry's annual meeting next week.

The systems are: the Velos Pro, a dual-pressure linear ion trap instrument; the Q Exactive, a benchtop quadrupole-Orbitrap LC-MS/MS system; and the Orbitrap Elite, a new hybrid mass spectrometer.

The Velos Pro offers linear quantitation of up to six orders of magnitude, scan speeds of up to 66,000 Da/sec, and new Trap-Higher Energy Collision Dissociation fragmentation, the company said. The Q Exactive, it said, combines quadrupole precursor selection and high-resolution accurate mass Orbitrap analysis to enable qual/quan workflows and offers resolving power of up to 140,000 FWHM in full-scan mode and maximum scan speed.

The Orbitrap Elite offers resolving power of greater than 240,000 FWHM at m/z 400 as well as a four-fold increase in scan speed compared to the previous generation of Orbitraps, the company said.

Bruker said this week that will launch its new Maxis Impact UHR-Qq-TOF mass spectrometer at ASMS.

The Maxis Impact is designed as a more affordable benchtop version of the company's Maxis 4G machine, and provides 40,000 FSR and 1 ppm mass accuracy while acquiring up to 50 full spectra per second, the company said.

Waters this week introduced its new Acquity UPLC I-Class system, which it said is its highest performing UPLC system ever.

According to the company, due to its minimal system volume, the instrument features the lowest system dispersion currently available, allowing for faster separations and enhancing mass spec sensitivity.

Agilent this week released its new Zorbax RRHG 300SB-C18 columns. Intended for the separation of intact proteins and protein digests, the columns offer faster sample analysis and better identification of post-translational modifications, the company said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.